M-802(Wuhan Yzy Biopharma/CSPC Pharmaceutical)

重组抗HER2和CD3人源化双特异性抗体

Report date: 2026/03/19 16:47:15

Base Information

Drug NameM-802(Wuhan Yzy Biopharma/CSPC Pharmaceutical)
Drug Alias NameAnti-HER2/anti-CD3 antibody - YZY BiopharmaM-802
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibodyBiologics > T cell engagers
Mechanisms of ActionCD3 T-cell engagersReceptor protein-tyrosine kinase erbB-2 antagonistsAnti-HER2 +[4] 
TargetsT cell surface glycoprotein CD3Receptor protein-tyrosine kinase erbB-2
Therapy Area/IndicationsSolid tumoursOvarian NeoplasmsStomach Neoplasms +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesWuhan Yzy Biopharma Co LtdCSPC Pharmaceutical Group Ltd
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesWuhan Yzy Biopharma Co Ltd
Inactive CompaniesN/A
Active IndicationsSolid tumoursOvarian NeoplasmsStomach Neoplasms +[4] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A